KOL Spotlight Interviews is a segment where we interview experts in various fields on their expertise and insights that continue to help shape the diagnostics and pharmaceutical industries. This month, we have the pleasure of welcoming Dr. Animesh Sinha, a renowned dermatologist from University at Buffalo. Below, we will learn more about diagnostic methods for autoimmune bullous dermatoses conditions.
Dermatophyte infections are difficult to diagnose clinically as they can resemble other skin disorders. Without proper diagnosis and treatment, dermatophyte infections can lead to permanent damage of the hair, skin, and nails. Molecular diagnostic testing of fungal infections allows for the accurate detection of dermatophytes that might be difficult to grow in culture, or in cases where a dermatophyte infection has already been treated, and allows for species-specific identification.
Meet Lisa Ann, a patient who was diagnosed with a rare autoimmune skin blistering disease after many misdiagnoses. She shares her story from the first symptoms and frustrations, testing and multiple doctor visits, and how she lives and manages this condition today. Check out this Patient Journey to hear from Lisa Ann and learn what diagnostic tests are available for these rare skin diseases.
Invasive Aspergillosis (IA) is an infection caused by Aspergillus. People with weakened immune systems or lung diseases are at a higher risk of developing IA. It is one of the most commonly under-detected diagnoses in ICU patients. Because symptoms are not specific, it is important to know which diagnostic tests can aid in early detection and management of IA.
Dr. Ruth Brignall completed a PhD in immunology and a post-doc in cancer biology. She joined Oxford Immunotec, first as a Medical Science Liaison (MSL) and more recently as a Global Medical Expert. Below, we will learn more about her experiences and insights in tuberculosis and SARS-CoV-2 diagnostics.
Less than a year after the World Health Organization (WHO) declared COVID-19 a global pandemic, the authorization of several novel COVID-19 vaccines has created hope for a healthier future. Recent studies have demonstrated that both humoral and cellular immunity play a role in protection from COVID-19. Additionally, the development of novel COVID-19 vaccines requires a look at the immune response in order to determine the effectiveness of the vaccine at preventing infection.
There is a need for continuous monitoring of therapeutic levels of TNF-α inhibitors to promote individualized treatment while affirming that patients receive the most accurate and cost-effective regimen available. With the MabTrack ELISA, clinicians can make effective adjustments based on semi-quantitative results and can facilitate simplified decision-making with their patients for improved long-term response.
SARS-CoV-2, commonly known as the coronavirus disease 2019 (COVID-19) poses an unprecedented public health crisis. While scientists and clinicians worldwide are still working to understand the virus, recent studies show possible onset of autoimmune diseases following COVID-19 infection.
The recent study conducted by De Meyer et al. demonstrated that EUROIMMUN ELISA and SIMOA (single molecule array) platform detected cerebral amyloidosis with equivalent accuracy through measuring the plasma Aβ42/Aβ40 ratio.
Previous
Page 3 of 3